secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001140361-25-017870
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech reports preclinical flu vaccine data with Infectimune at IMMUNOLOGY2025
--------------------------------------------------------------------------------

- Infectimune-based flu vaccine elicited multifunctional, influenza-specific CD4 T cells with cytotoxic characteristics in preclinical studies.
- Preclinical ferret studies showed neutralization of H3N2 influenza strains from 2014 to 2021 using COBRA antigens.
- Studies were funded by NIAID's CIVR-HRP and presented by Dr. Sant (U of Rochester) and Dr. Allen (Cleveland Clinic).
- Company reaffirms focus on VERSATILE-003 Phase 3 trial for Versamune HPV in HPV16-positive HNSCC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125017870/0001140361-25-017870-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125017870/ef20048584_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-017870

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer